Dermapharm Holding SE: Annual General Meeting resolves dividend distribution
of EUR 0.88 per share

EQS-News: Dermapharm Holding SE / Key word(s): AGM/EGM
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution
of EUR 0.88 per share

27.06.2024 / 18:15 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Dermapharm Holding SE: Annual General Meeting resolves dividend distribution
of EUR 0.88 per share

* 2024 outlook confirmed

  * Board of Management and Supervisory Board actions ratified with large
    majority

* Shareholders resolve dividend payment of EUR 0.88 per share

* Distribution ratio: approximately 78% of consolidated net profit

Grünwald, 27 June 2024 - Dermapharm Holding SE ("Dermapharm"), a rapidly
growing manufacturer of branded pharmaceuticals and other healthcare
products, today held its Annual General Meeting for financial year 2024.
90.3% of the share capital was in attendance at the Annual General Meeting,
which was held in person. The majority of shareholders approved the
management's proposals under every agenda item.

The Annual General Meeting ratified the actions of all members of the Board
of Management and of the Supervisory Board for financial year 2023 with a
98.6% and 91.5% majority of votes cast, respectively. The Annual General
Meeting acted on the recommendation of the Board of Management and the
Supervisory Board to distribute a dividend of EUR 0.88 per share carrying
dividend rights. The total distribution amounts to EUR 47.4 million,
representing a distribution ratio of approximately 78% of the distributable
consolidated net income.

Grant Thornton AG Wirtschaftsprüfungsgesellschaft was re-elected as the
auditor for the current financial year. RSM Ebner Stolz GmbH & Co. KG
Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft was chosen as
auditor for the sustainability reporting. The detailed results of the voting
for each agenda item are available in the Annual General Meeting section of
the Company website https://ir.dermapharm.de.

In their retrospective on financial year 2023, the Board of Management and
Supervisory Board emphasised the particular strength and resilience of the
corporate strategy. Dermapharm succeeded in maintaining its growth
trajectory despite a difficult macroeconomic environment and the scheduled
end of vaccine production. The Board of Management and the Supervisory Board
expressed their special thanks to the entire workforce for their
extraordinary dedication and commitment. The Board of Management concluded
by providing an outlook for the remainder of financial year 2024.

"We have used 2023 to make the company fit for the future. The investment in
the acquisition of Arkopharma and Montavit is a booster for our
internationalisation. With targeted investments in photovoltaics and energy
efficiency improvements, for example, we are able to reduce costs and offer
our customers a sustainable supply of pharmaceuticals made in Europe," said
Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.

Based on the course of business to date in 2024, the Board of Management
confirms the guidance for 2024 and expects consolidated revenue of EUR
1,170-1,210 million and adjusted consolidated EBITDA of EUR 305-315 million.

Company profile

Dermapharm - Pharmaceutical Excellence "Made in Europe"

Dermapharm is an innovative and rapidly growing manufacturer of branded
pharmaceuticals and other healthcare products. Founded in 1991, the Company
is based in Grünwald near Munich. In addition to its main location in Brehna
near Leipzig, Dermapharm also operates other production, development and
distribution locations in Germany, the rest of Europe and the United States.

In the "Branded pharmaceuticals" segment, Dermapharm has more than 1,300
marketing authorisations with more than 400 active pharmaceutical
ingredients. Dermapharm's portfolio of pharmaceuticals is tailored to
selected therapeutic areas in which the Company is a market leader,
especially in Germany. The Company's integrated business model extends from
in-house product development and production through quality management and
logistics to the distribution of branded pharmaceuticals by a trained
pharmaceutical sales force.

Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics,
medical devices, herbal extracts and medicinal cannabis in its "Other
healthcare products" segment. In this segment, Dermapharm can tap the
expertise of Arkopharma, the market leader for herbal food supplements in
France, and the Spanish company Euromed S.A., a leading global manufacturer
of herbal extracts and plant-based active ingredients for the
pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm also operates the "Parallel import business" segment under the
axicorp brand. axicorp imports originator pharmaceuticals from other EU
Member States and resells them to pharmaceuticals wholesalers and pharmacies
in Germany. This enables axicorp to benefit from the different pricing
structures in the individual EU member states. Based on revenue, axicorp is
currently the sixth largest parallel importer in Germany.

With a consistent R&D strategy and numerous successful product and company
acquisitions and by stepping up its internationalisation efforts, the Group
is continuously optimising its business activities and seeks external growth
opportunities in addition to organic growth.

Contact

Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 - 64186-233

E-mail: ir@dermapharm.com


---------------------------------------------------------------------------

27.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Dermapharm Holding SE
                   Lil-Dagover-Ring 7
                   82031 Grünwald
                   Germany
   Phone:          +49 (0)89 64 86-0
   E-mail:         ir@dermapharm.com
   Internet:       ir.dermapharm.de
   ISIN:           DE000A2GS5D8
   WKN:            A2GS5D
   Indices:        SDAX
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Stuttgart, Tradegate Exchange
   EQS News ID:    1935093

End of News EQS News Service
---------------------------------------------------------------------------

1935093 27.06.2024 CET/CEST